Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Authors :: Cannon, Timothy Lewis
Rothe, Michael
Garrett-Mayer, Elizabeth
Chiu, Vi Kien
Hwang, Jimmy J.
Vijayvergia, Namrata
Alese, Olatunji B.
Dib, Elie G.
Duvivier, Herbert Leon
Klute, Kelsey
Sahai, Vaibhav
Ahn, Eugene R
Behl, Deepti
Sinclair, Sarah
Thota, Ramya
Urba, Walter John
Yang, Eddy Shih-Hsin
Grantham, Gina N.
Halabi, Susan
Schilsky, Richard L.
Source :: Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, p546-546, 1p
Publication Year :: 2023

Full Text Access

Tools